Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases
| Autor: | Ana Catarina Silva, J.M. Sousa Lobo, Maria Helena Amaral, Sara C. Cunha, Hugo Almeida |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Nanoemulsions Solid lipid nanoparticles 02 engineering and technology Pharmacology 03 medical and health sciences In vivo Drug Discovery Solid lipid nanoparticle Medicine Adverse effect Liposome Nanostructured lipid carriers Nasal/intranasal administration business.industry Neurodegenerative diseases 021001 nanoscience & nanotechnology Review article 030104 developmental biology Liposomes Microemulsions Drug delivery Nasal administration Nose-to-brain 0210 nano-technology business Ex vivo |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| ISSN: | 1381-6128 |
| DOI: | 10.2174/1381612824666171128105305 |
| Popis: | Background Current treatments for neurodegenerative diseases are challenging, due to the absence of full effective medicines. One of the major problems associated to these is the occurrence of non-targeting events, which leads to adverse effects and requires frequent dose administration. Methods Researches have been performed to develop new drug delivery systems administrated by alternative routes. For example, the direct nose-to-brain delivery of drugs by means of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), have been showing promising results. Results Among the advantages of intranasal administration is the avoidance of passing the blood-brain barrier (BBB) to reach the central nervous system (CNS), allowing the direct delivery of drugs to the brain by a non-invasive way, minimizing systemic exposure and prolonging residence time. This review article discusses the advantages of using SLN and NLC for direct nose-to-brain drug delivery. A brief reference to other lipid-based carriers (liposomes, nanoemulsions and microemulsions) is also provided. Conclusion The benefits of using SLN and NLC for improve nasal drug delivery have been demonstrated by in vitro, ex vivo and in vivo experiments. However, more in vivo animal studies are needed for advance to human clinical trials and reach clinics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|